Sep. 10 at 12:24 AM
$RFL Given your familiarity with NPC, I think the most important unknown is not whether cyclodextrin can mobilize cholesterol, but whether the trial demonstrates a sufficiently large clinical effect on disease progression after 96 weeks. That single number will likely determine whether RFL remains a
$100M company or becomes a multi-billion-dollar rare disease company.
